Medicine
Pharmaceuticals
Product Number : 10885-001-01
Antineoplastic Agent
Indication
First line cytotoxic therapy for advanced HIV-associated Kaposi's sarcoma.
Benefit
To maximize tumor targeting further, the DaunoXome liposomes are filtered so the particles are within the 35-nm-to-65-nm range; tumor blood vessels have increased permeability to particles in this range. Another important benefit of this formulation is that it can be used concurrently with the more commonly prescribed antiretrovival agents without increased risk.
